EQS-News: Carl Zeiss Meditec AG / Key word(s): Regulatory Approval ZEISS VISUMAX 800 with SMILE pro software receives ...

Der deutsche Medizintechnik-Konzern expandiert im asiatischen Markt mit innovativer Augenchirurgie-Technologie trotz aktuell herausfordernder Börsensituation.

Total Play reported EBITDA of Ps. 20,956 million, up 14% from Ps. 18,361 million in the prior year, with the EBITDA margin increasing two-percentage points to 47%. Operating income grew to Ps. 3,844 ...

Aligne Wealth Advisors Investment Management (AWAIM) proactively manages risk and return opportunities as markets evolve. This forward-looking approach recently led to strategic portfolio adjustments ...

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /PRNewswire/ ...

The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without ...

ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the ...

In der Augenmedizin ist der Carl Zeiss Meditec der Weltmarktführer. Die Aktie des MDAX-notierten Medizintechnik-Spezialisten ...

A significant factor in the company's growth is the launch of the Visumax 800 in China. However, JPMorgan is skeptical about the demand for this higher-priced premium product, given the subdued demand ...

Am Donnerstag passte JPMorgan-Analystin Anchal Verma das Kursziel für Carl Zeiss Meditec (ETR: AFXG) AG (AFX:GR) (OTC: CZMWY) von 40,00€ auf 41,00€ an, behielt aber die Einstufung "Underweight" bei. D ...